CymaBay price target raised to $21 from $19 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on CymaBay to $21 from $19 and keeps a Buy rating on the shares post the Q2 report. The analyst says the IDEAL study is set to challenge the current benchmark and reset expectations for second line treatment in primary biliary cholangitis.